Description

Product Description

Vosoritide acetate is a C-type natriuretic peptide (CNP) analogue engineered to selectively activate natriuretic peptide receptor B (NPR2), a key receptor involved in bone elongation and cartilage homeostasis. Through its high-affinity binding to NPR2, Vosoritide stimulates cyclic guanosine monophosphate (cGMP) production, which in turn promotes chondrocyte proliferation and differentiation in the growth plate cartilage, facilitating endochondral bone formation.

In physiological conditions, CNP is produced locally by chondrocytes and acts in an autocrine/paracrine manner to regulate the pace of bone growth. However, CNP is rapidly degraded by neutral endopeptidases (NEP), leading to limited biological availability. Vosoritide acetate incorporates amino acid substitutions that confer enhanced enzymatic stability and longer half-life, enabling sustained NPR2 activation and a prolonged anabolic effect on bone tissue in research models.

Vosoritide has been widely utilized to study achondroplasia, the most common form of genetic dwarfism caused by gain-of-function mutations in fibroblast growth factor receptor 3 (FGFR3). These mutations suppress chondrocyte proliferation and inhibit bone growth through excessive activation of the MAPK/ERK pathway. Vosoritide counteracts this suppression by enhancing cGMP-mediated signaling, which antagonizes FGFR3 downstream effects. Consequently, it restores chondrocyte proliferation, increases matrix synthesis, and promotes growth plate expansion, providing a valuable tool for skeletal dysplasia research.

Beyond bone growth, Vosoritide acetate has applications in broader cartilage biology, tissue regeneration, and cell signaling studies. It serves as a key reagent to explore NPR2-cGMP signaling networks, as well as cross-talk between FGFR3, PI3K/AKT, and ERK1/2 pathways. Research also suggests roles for Vosoritide in extracellular matrix remodeling and mechanotransduction during cartilage maintenance.

As a lyophilized acetate salt, Vosoritide acetate offers excellent solubility, high purity (≥99%), and reproducible bioactivity across in vitro and ex vivo systems. It remains stable under proper storage conditions and can be easily reconstituted for use in biochemical, cellular, or organoid-based studies related to chondrogenesis and skeletal development.

Product Specifications

Mechanism of Action

Vosoritide acetate exerts its biological activity through potent agonistic activation of NPR2, a transmembrane guanylyl cyclase receptor abundantly expressed in epiphyseal chondrocytes. Upon binding, NPR2 converts GTP to cGMP, which serves as a second messenger to activate protein kinase G (PKG). PKG phosphorylates a range of downstream targets that enhance matrix synthesis, cell proliferation, and cartilage differentiation.

The cGMP–PKG signaling axis induced by Vosoritide inhibits FGFR3–MAPK/ERK signaling, which is hyperactivated in achondroplasia and other skeletal dysplasias. By dampening FGFR3 signaling, Vosoritide rescues the repressed chondrocyte proliferation rate and prevents premature hypertrophic differentiation. This balance between cGMP and MAPK activity is crucial for normal endochondral ossification and longitudinal bone growth.

Vosoritide’s mechanism also influences the extracellular matrix (ECM) microenvironment. cGMP elevation enhances synthesis of collagen type II and aggrecan, vital components of cartilage structure and biomechanical integrity. Additionally, it reduces matrix metalloproteinase (MMP) expression, slowing ECM degradation and promoting regenerative remodeling.

Emerging research indicates Vosoritide may regulate mechanotransduction through TRPV4 and integrin-linked kinase (ILK) pathways, linking NPR2 activation to cytoskeletal dynamics and chondrocyte mechanosensitivity. Moreover, the peptide has been shown to promote angiogenic signaling at the chondro-osseous junction, facilitating the vascular invasion essential for bone elongation.

Overall, Vosoritide acetate represents a unique molecular probe for dissecting cGMP-dependent signaling in skeletal development and for identifying potential modulators of growth plate physiology, cartilage maintenance, and bone regeneration.

Side Effects

In preclinical research, Vosoritide acetate displays favorable safety and stability profiles. However, excessive activation of NPR2 can lead to transient hypotension or altered vascular tone due to systemic natriuretic signaling. In cell-based assays, high concentrations may induce off-target cGMP accumulation, influencing unrelated signaling cascades.

Proper handling and experimental calibration are essential to maintain physiologic relevance. Researchers should reconstitute the lyophilized peptide using sterile techniques and avoid repeated freeze–thaw cycles to preserve structural integrity and biological activity.

Vosoritide acetate is supplied strictly for laboratory research use only, and not for human administration or diagnostic purposes.

Disclaimer

This product is intended for research use only. Vosoritide acetate should not be used in humans or animals. All experiments must comply with institutional safety and biosafety regulations.

Keywords

Vosoritide acetate, BMN 111, NPR2 agonist, CNP analogue, chondrocyte proliferation peptide, bone growth regulator, endochondral ossification, FGFR3 pathway antagonist, skeletal dysplasia research, cartilage differentiation peptide

Shipping Guarantee

All peptide reagents are shipped under temperature-controlled conditions to ensure bioactivity retention. Each batch is validated by HPLC and MS analysis and accompanied by a Certificate of Analysis (COA) for traceability and reproducibility.

Trade Guarantee

We guarantee ≥99% purity, batch-to-batch consistency, and secure international transactions. All products meet global laboratory reagent standards and include technical data upon request.